Tag: Immunotherapy for NPC

Home / Immunotherapy for NPC

Categories

Toripalimab-tpzi is approved by the FDA for nasopharyngeal carcinoma

In October 2023, the FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine as the first-line treatment for people with locally advanced nasopharyngeal canc...
immunotherapy-for-npc

We Are Online! Chat With Us!
Scan the code